$BMRN
BioMarin Pharmaceutical Inc.
Rare disease biotech company with gene therapy and enzyme replacement treatments.
BMRN key facts as of November 14, 2026
- Latest AI research report
- BMRN Stock: Growth, Debt and Pipeline Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Strong Buy (5 Strong Buy, 16 Buy, 7 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $92.36 mean (range $59.00 to $122.00) (as of November 20, 2026)
- Sector
- Healthcare
Analysis from Nov 14, 2026
BMRN Stock: Growth, Debt and Pipeline Risks
BioMarin reported 32% revenue growth and beat its latest earnings estimate, while analyst targets imply substantial upside from Friday’s close. Negative trailing earnings, acquisition-related debt, and recent target cuts keep the outlook mixed.
Previous Reports
BMRN FAQ
What is StockAlpha's latest view on BMRN?
StockAlpha's latest AI research report on BioMarin Pharmaceutical Inc. (BMRN), "BMRN Stock: Growth, Debt and Pipeline Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. BioMarin reported 32% revenue growth and beat its latest earnings estimate, while analyst targets imply substantial upside from Friday’s close. Negative trailing earnings, acquisition-related debt, and recent target cuts keep the outlook mixed.
When was the BMRN research last updated?
The most recent BMRN report was published on November 14, 2026.
What do analysts expect for BMRN?
As of November 1, 2026, the analyst consensus on BMRN is Strong Buy (5 Strong Buy, 16 Buy, 7 Hold, 0 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $92.36 mean (range $59.00 to $122.00).
Is this BMRN research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft BioMarin Pharmaceutical into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on BioMarin Pharmaceutical's peers: Today's sector-level news and moves around the stock